Starling Oncology Overview
Get informed when a big investor buys or sells
+ Follow52.06
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for STLN is 52.06. That is above the sector sector average of 9.98. Investors often review this figure alongside Starling Oncology's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, STLN currently prints 52.06 for PEG ratio, while the sector average sits near 9.98. That is roughly 421.5% above the sector mean. Large gaps often invite a closer look at Starling Oncology's growth, margins, and balance sheet.
A PEG ratio of 52.06 for Starling Oncology is not 'good' or 'bad' on its own. Compare it with the peer average (9.98) and with STLN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting STLN's PEG ratio (52.06), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
